NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
MEDICLIN 9M 2025 Financial Performance and Business Outlook FAQ
TL;DR
MEDICLIN's 42% operating profit surge to EUR 48.9 million demonstrates strong financial performance and competitive positioning in the healthcare market.
MEDICLIN achieved 5.1% sales growth to EUR 586.9 million through segment optimization while maintaining stable 86.8% capacity utilization across operations.
MEDICLIN's improved financial results support continued healthcare delivery across 31 clinics and 6 care facilities, enhancing patient care for communities.
MEDICLIN transformed its acute segment from a EUR 3.8 million loss to EUR 0.7 million profit while growing post-acute sales by 9.3%.
Found this article helpful?
Share it with your network and spread the knowledge!
MEDICLIN achieved consolidated group sales of EUR 586.9 million (up 5.1% from 9M 2024) and a group operating result of EUR 48.9 million (up from EUR 34.5 million in 9M 2024), with overall capacity utilization remaining stable at 86.8%.
The post-acute segment showed strong growth with sales increasing 9.3% to EUR 394.6 million and segment operating result rising by EUR 9.6 million to EUR 47.6 million, while the cost of materials ratio improved to 19.5%.
The acute segment saw sales decrease by 3.2% due to the sale of MEDICLIN Herzzentrum Coswig, but the segment operating result improved significantly to EUR 0.7 million from a loss of EUR -3.8 million in the same period last year.
MEDICLIN's Management Board confirms guidance for 2025 with consolidated group sales expected to grow between 2.0% and 5.0% and consolidated group EBIT projected between EUR 53.0 million and EUR 64.0 million.
CFO Tino Fritz comments that business development remains solid despite current conditions and typical seasonal effects, and the company expects to achieve its original annual guidance and successfully conclude the current financial year.
The interim report as of 30 September 2025 is available in German and English at www.mediclin.de.
For further information, contact Investor Relations representative Ender Gulcan at ender.guelcan@mediclin.de or +49781/488-326.
Personnel expenses increased in the post-acute segment by 9.4% to EUR 205.0 million mainly due to salary increases and higher employee numbers, while decreasing in the acute segment by 4.8% to EUR 101.0 million.
Curated from NewMediaWire
